Member Info for ConsDoms

Https://www.theguardian.com/business/2025/mar/17/astrazeneca-biotech-cancer-cell-therapy-esobiotec-imfinzi

Nonsense Boom and you know it. You started from completely out of nowhere with a very aggressive attack on Hw calling him a rat. You didnt pose one counter view on the science. (Stu does that to be fair). I noticed somebody thought you were vile and it got over 20 Recommends (that is from those who could be bothered, I wasnt one of them)

Study Overview

Brief Summary

This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 18 evaluable subjects will be enrolled. Evaluable subjects are defined as those who have received an infusion of HG-CT-1.

Primary clinical objectives:

i. Determine the safety of HG-CT-1 based on the proportion of subjects infused with HG-CT-1 who experience a dose limiting toxicity (DLT).

Secondary clinical objectives:

i. Estimate the efficacy of HG-CT-1 according to standard clinical response criteria for AML.

ii. Estimate overall survival of evaluable subjects. iii. Estimate progression-free survival of evaluable subjects. iv. Estimate duration of response in evaluable subjects who achieve a response.

Secondary scientific objectives:

i. Describe the persistence and trafficking of HG-CT-1. ii. Describe HG-CT-1 bioactivity and its predictors.

Show less

Official Title

Phase 1 Study of Anti-FLT3 Chimeric Antigen Receptor-redirected T Cells in Subjects with Relapsed/refractory Acute Myeloid Leukemia (AML)

Study Overview

Brief Summary

This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 18 evaluable subjects will be enrolled. Evaluable subjects are defined as those who have received an infusion of HG-CT-1.

Primary clinical objectives:

i. Determine the safety of HG-CT-1 based on the proportion of subjects infused with HG-CT-1 who experience a dose limiting toxicity (DLT).

Secondary clinical objectives:

i. Estimate the efficacy of HG-CT-1 according to standard clinical response criteria for AML.

ii. Estimate overall survival of evaluable subjects. iii. Estimate progression-free survival of evaluable subjects. iv. Estimate duration of response in evaluable subjects who achieve a response.

Secondary scientific objectives:

i. Describe the persistence and trafficking of HG-CT-1. ii. Describe HG-CT-1 bioactivity and its predictors.

Show less

Official Title

Phase 1 Study of Anti-FLT3 Chimeric Antigen Receptor-redirected T Cells in Subjects with Relapsed/refractory Acute Myeloid Leukemia (AML)

Didn’t you aggressively attack first? I think you called Hw a rat? You didn’t have to believe is view on the science (or any body else’s view on here for that matter)

Not quite sure how many shares will be in issue by the end of 2Q25 but if HEMO have three very positive patient results Vlad may be in a strong position to strike a very favorable deal. that's all i can really hope for now. I used to be glass half full...

Boom. I get your skepticism and lack of trust. but the inference is that they have mugged MD Anderson also

I dont think HW has been challenged on the science but happy to be corrected. What did the challenger say?

Yeh, really dont get Booms post. Haywain has only ever given a view on the science and I dont think he has been proven wrong at the moment

But as per the title of the thread there is a bigger picture - we just need to get to day 28 of patient three - then, in my humble, things could change dramatically...

HT would you mind explaining to me? 6.468 bought against 436 sold (albeit only 21nr tranasctions)

Micky. It is all about the data now. But us minions may not get any insight until the third patient is through the 28 days. If the data is good then I guess this SP will be irrelevant, we shall see. Im not sure how HEMO keep going to the end of May. But perhaps if the data is strong (from the first patient) they may get a little assistance - hopefully discussions are being had in that regard at the moment

Interesting food SB

Yeh, he seems like real scum. (why bring the lovely Cheryl in to it?)

Not quite sure i follow MrJ. JHFH has openly detailed his involvement in the recent CLN. He (and others) did it in an attempt to protect their existing investment (as they didn't want another placing upon which the shares would be flipped by parties who have no interest in HEMO). Feels like they did it as a last resort? Are you saying HEMO has not been short sold over the last couple of years?

Good perspective Pingu. Perhaps there is fatigue amongst PIs. But this really is about the science now and that science has commenced its ultimate test. PIs won’t really matter if it passes..

Best wishes to the patient.

and good luck to those who invested and stayed.

https://www.londonstockexchange.com/news-article/HEMO/first-in-human-treatment-with-hg-ct-1/16910936

Hopefully not but there is a possibility we won’t hear anything for 6 months once first infusion known

Please correct my rough maths DCT. you are 85% down so your average is ~£20 new money?(5p old money). £20 x 3.6m is £72mcap. why are you so certain any rerate wont get your investment back - what are you expecting mcap to be if early trial results are strong? Im just asking - but you must have had an idea about the science and the potential value to part with 33 large

Your cynicism is not unfounded IG. perhaps like me you thought the market worked on simple supply and demand. and those that had a bit of insight had to keep tight lipped under pain of death. but clearly that is not the case - far from it in fact. so at the risk of repeating myself, I for one am glad if the suits got played by a body of genuine investors (to give the company a little leg up). hopefully the science will be the main talking point soon.